ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a...
135 insider purchases on record · latest filing 2026-09-30.
Insiders have also filed 114 sale transactions at ADRX.